Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Gene silencing --- RNA --- Gene Silencing. --- RNA Interference. --- Gene silencing. --- RNA.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Epigenetics. --- Gene silencing. --- Gene inactivation --- Inactivation, Gene --- Silencing, Gene --- Genetic regulation --- Genetics

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Neurodegenerative diseases (NDs) are a heterogeneous group of disorders affecting the central nervous system. Despite significant differences in their causes, neuropathological abnormalities, and clinical outcomes, some similarities can be found among them, as for example: 1) frequent aggregation and deposition of misfolded proteins, 2) common molecular mechanisms leading to neurodegeneration, and 3) certain overlap in symptoms and clinical features. To date, there is no cure that could stop or delay the progression of these diseases. The advent of advanced gene therapy techniques such as gene silencing and gene editing opened a new avenue for the development of therapeutic strategies for NDs. The discovery of the RNA interference (RNAi) mechanism, in 1998, by Andrew Fire and Craig Mello allowed an important boost to the gene therapy field, providing a potential therapeutic strategy to treat inherited dominant genetic disorders. The use of small RNA sequences to control the expression of disease-causing genes rapidly implemented in the preclinical studies for different diseases. In the field of NDs, several successful studies using this technology proved its potential as a therapeutic option. However, issues like the type of delivery system (non-viral versus viral) or the potential toxicity of the small RNA molecules, made the translation of gene silencing therapeutics to human application very slow and difficult. Recently, a new hope in the gene therapy field emerged with the development of gene editing techniques like TALENs or CRISPR/Cas9 systems. The opportunity of editing or deleting gene sequences drove the scientific community euphoric, with an enormous increase in the number of published studies using this type of techniques. Recently, the first clinical trial using one of these systems was approved in China. For NDs, gene-editing technology also represents an important therapeutic option, and the first preclinical studies are now being published, showing the potential accomplishment for this technology.

Gene silencing --- Long non-coding RNAs --- RNA interference --- Neurodegenerative diseases --- CRISPR/Cas9 --- Neurodegeneration --- Gene editing --- Antisense oligonucleotides --- Neuroinflammation --- iPS cells --- Gene silencing --- Long non-coding RNAs --- RNA interference --- Neurodegenerative diseases --- CRISPR/Cas9 --- Neurodegeneration --- Gene editing --- Antisense oligonucleotides --- Neuroinflammation --- iPS cells

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact

Medicine --- Immunology --- organ transplantation --- marginal donors --- expanded criteria donors --- machine perfusion --- organ allocation --- graft survival --- delayed graft function --- antigen silencing --- organ transplantation --- marginal donors --- expanded criteria donors --- machine perfusion --- organ allocation --- graft survival --- delayed graft function --- antigen silencing

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book examines how post-transcriptional mechanisms control endocrine function. This includes newly identified regulatory mechanisms involved in hormone biosynthesis, control of hormone receptors and the outputs of hormone mediated signal transduction. Chapters address endocrine hormones including protein peptide/peptide, steroid, and non-steroidal hormones. The impacts of these mechanisms on disease and health are covered, providing a novel update to the scientific literature. Post-transcriptional regulatory mechanisms play an essential role in controlling dynamic gene expression. The outcome of this regulation includes control of the amount, timing, and location of protein expression. Regulation is mediated by cis-acting RNA sequences and structures and transacting RNA binding proteins and non-coding RNAs, including microRNAs. Recent advances in characterization of these regulatory factors have revealed enormous regulatory potential.

Physiology --- Human Anatomy & Physiology --- Health & Biological Sciences --- Endocrinology. --- RNA interference. --- Co-suppression (RNA interference) --- Interference, RNA --- Post-transcriptional gene silencing --- RNA silencing --- RNAi (RNA interference) --- Internal medicine --- Hormones --- Gene silencing --- Human physiology. --- Gene expression. --- Human Physiology. --- Gene Expression. --- Genes --- Genetic regulation --- Human biology --- Medical sciences --- Human body --- Expression --- Endocrinology .